Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 20, 2025 | June 24, 2025 |
| Charlotte's Web Holdings, Inc.CWBHF · Entity 2770 | Director | February 01, 2024 | February 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 20, 2025 · Filed June 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,213 |
Reported balance
After 2025-06-20 transaction · row 1
1 source rowRow 1 · 2025-06-20 · Grant · Acquired 14,164 · Balance 50,213 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.
Charlotte's Web Holdings, Inc.
Report date February 01, 2024 · Filed February 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 644,061 |
Reported balance
After 2024-02-01 transaction · row 1
1 source rowRow 1 · 2024-02-01 · Exercise / conversion · Acquired 441,176 · Balance 644,061 F1: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-01 · Exercise / conversion · Disposed 441,176 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2: The restricted stock unit agreement provides that the restricted stock units vest in 1 installment on the first anniversary of the restricted stock unit's grant date. The restricted stock units were granted on 7/1/2023. The Company accelerated all of the Section 16 insiders' restricted stock units on 2/1/2024 other than the CEO's. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc.
F2: The restricted stock unit agreement provides that the restricted stock units vest in 1 installment on the first anniversary of the restricted stock unit's grant date. The restricted stock units were granted on 7/1/2023. The Company accelerated all of the Section 16 insiders' restricted stock units on 2/1/2024 other than the CEO's.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SHARPS COMPLIANCE CORP
Report date August 22, 2022 · Filed August 23, 2022
Section 16 reporting ended · disclosed 2022-08-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-22 · Other · Disposed 43,065 · Balance 43,065 F1: Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended. F2: On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. F3: Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. Row 2 · 2022-08-23 · Disposition to issuer · Disposed 43,065 · Balance 0 F1: Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended. F2: On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. F3: Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended.
F2: On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding.
F3: Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2025 Filed Jun 24, 2025 21:14 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 14,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-004072 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,213 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:35 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-003910 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,049 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 17:43 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionRestricted Stock Unit · Derivative | 441,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001750155-24-000004 · wk-form4_1707173008.xml · derivative · entry 2 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 441,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2 · derivative.exercise_date: The restricted stock unit agreement provides that the restricted stock units vest in 1 installment on the first anniversary of the restricted stock unit's grant date. The restricted stock units were granted on 7/1/2023. The Company accelerated all of the Section 16 insiders' restricted stock units on 2/1/2024 other than the CEO's. F2 · derivative.expiration_date: The restricted stock unit agreement provides that the restricted stock units vest in 1 installment on the first anniversary of the restricted stock unit's grant date. The restricted stock units were granted on 7/1/2023. The Company accelerated all of the Section 16 insiders' restricted stock units on 2/1/2024 other than the CEO's. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 17:43 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionCommon Shares | 441,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001750155-24-000004 · wk-form4_1707173008.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 16:46 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | GrantRestricted Stock Unit · Derivative | 441,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001750155-23-000050 · wf-form4_168858990611073.xml · derivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,176 Underlying: Common Shares · 441,176 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2 · derivative.exercise_date: The restricted stock unit agreement provides that the restricted stock unit vests in 1 installment on 7/1/2024. F2 · derivative.expiration_date: The restricted stock unit agreement provides that the restricted stock unit vests in 1 installment on 7/1/2024. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 11:30 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionRestricted Stock Unit · Derivative | 163,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001750155-23-000044 · wf-form4_168753420099072.xml · derivative · entry 2 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 163,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2 · derivative.exercise_date: The restricted stock unit agreement provides that the restricted stock unit vests in full on the first anniversary of the restricted stock unit's grant date. The restricted stock unit was granted on 6/22/2022. F2 · derivative.expiration_date: The restricted stock unit agreement provides that the restricted stock unit vests in full on the first anniversary of the restricted stock unit's grant date. The restricted stock unit was granted on 6/22/2022. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 11:30 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionCommon Shares | 163,043 | $0.18 | $28,793.39 |
DisclosureSEC source: 0001750155-23-000044 · wf-form4_168753420099072.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-003963 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,278 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document |
| August 23, 2022 Filed Aug 23, 2022 11:09 UTC | SHARPS COMPLIANCE CORP SMED · Entity 124114 | Disposition to issuerCommon Stock | 43,065 | $8.75 | $376,818.75 |
DisclosureSEC source: 0000898770-22-000083 · wf-form4_166126736330850.xml · nonDerivative · entry 2 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended. F2 · shares: On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. F3 · shares: Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 11:09 UTC | SHARPS COMPLIANCE CORP SMED · Entity 124114 | OtherCommon Stock | 43,065 | $8.75 | $376,818.75 |
DisclosureSEC source: 0000898770-22-000083 · wf-form4_166126736330850.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,065 F1 · shares: Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended. F2 · shares: On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. F3 · shares: Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 13:49 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | GrantRestricted Stock Unit · Derivative | 163,043 | $0.46 | $74,999.78 |
DisclosureSEC source: 0001750155-22-000078 · wf-form4_165609293976392.xml · derivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,043 Underlying: Common Shares · 163,043 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2 · derivative.exercise_date: The restricted stock unit agreement provides that the restricted stock unit vests in 1 equal installment on 6/22/2023. F2 · derivative.expiration_date: The restricted stock unit agreement provides that the restricted stock unit vests in 1 equal installment on 6/22/2023. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 10:13 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionRestricted Stock Unit · Derivative | 16,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001750155-22-000064 · wf-form4_165512958748368.xml · derivative · entry 2 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. F2 · derivative.exercise_date: The restricted stock unit agreement provides that the restricted stock unit vests in full on the first anniversary of the restricted stock unit's grant date. The restricted stock unit was granted on 6/9/2021. F2 · derivative.expiration_date: The restricted stock unit agreement provides that the restricted stock unit vests in full on the first anniversary of the restricted stock unit's grant date. The restricted stock unit was granted on 6/9/2021. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 10:13 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | Exercise / conversionCommon Shares | 16,164 | $0.52 | $8,355.17 |
DisclosureSEC source: 0001750155-22-000064 · wf-form4_165512958748368.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit represents a contingent right to receive one common share of Charlotte's Web Holdings, Inc. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-004302 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,778 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2023 annual meeting of the Company's stockholders or June 8, 2023. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 16:55 UTC | SHARPS COMPLIANCE CORP SMED · Entity 124114 | GrantRestricted Stock Award | 12,932 | $0.00 | $0.00 |
DisclosureSEC source: 0000898770-21-000128 · wf-form4_163338091148044.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,065 F1 · shares: Grant of restricted shares for the Company's common stock issued under 2010 Sharps Compliance Stock Plan per Sharps Compliance Non-Employee Directors and Committee Compensation. The grant represents the equity portion of the non-employee director and committee compensation services to be provided October 1, 2021 - September 30, 2022. The restricted shares are subject to the terms and conditions of the underlying Restricted Stock Award Agreement and vest 25% on each of December 31, 2021; March 31, 2022; June 30, 2022 and September 30, 2022. F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes Common Stock and Restricted Stock Awards. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:20 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004431 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document |
| October 01, 2020 Filed Oct 28, 2020 17:36 UTC | SHARPS COMPLIANCE CORP SMED · Entity 124114 | GrantRestricted Stock Award | 14,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000898770-20-000096 · wf-form4_160392097016445.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,133 F1 · shares: Grant of restricted shares for the Company's common stock issued under 2010 Sharps Compliance Stock Plan per Sharps Compliance Non-Employee Directors and Committee Compensation. The grant represents the equity portion of the non-employee director and committee compensation services to be provided October 1, 2020 - September 30, 2021. The restricted shares are subject to the terms and conditions of the underlying Restricted Stock Award Agreement and vest as follow: 25% on December 31, 2020, 25% on March 31, 2021, 25% on June 30, 2021 and 25% on September 30, 2021. F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes Common Stock and Restricted Stock Awards. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:52 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001361 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,652 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 17:11 UTC | SHARPS COMPLIANCE CORP SMED · Entity 124114 | GrantRestricted Stock Award | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000898770-19-000067 · wf-form4_156996428692870.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Grant of restricted shares for the Company's common stock issued under the 2010 Sharps Compliance Stock Plan per the Sharps Compliance Non-Employee Directors and Committee Compensation. The grant represents the equity portion of the non-employee director and committee compensation services to be provided October 1, 2019 - September 30, 2020. The restricted shares are subject to the terms and conditions of the underlying Restricted Stock Award Agreement and vest as follows: 25% on December 31, 2019, 25% on March 31, 2020, 25% on June 30, 2020 and 25% on September 30, 2020. F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes Common Stock and Restricted Stock Awards. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001392 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,545 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| October 23, 2018 Filed Oct 25, 2018 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-007240 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest immediately prior to the Anika Therapeutics, Inc. 2019 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.